A Prospective Observational Study of Stereotactic Body Radiotherapy for Favorable Risk Prostate Cancer

A Prospective Observational Study of Stereotactic Body Radiotherapy for Favorable Risk Prostate Cancer - A Prospective Observational Study of Stereotactic Body Radiotherapy for Favorable Risk Prostate Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045391

Enrollment

Registered

2021-09-06

Start date

2020-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Primary adenocarcinoma of the prostate 2) T1c-T3bN0M0 (UICC TNM 8th Edition) 3) Age >= 20 years old 4) ECOG-PS 0-2 5) No previous pelvic radiotherapy 6) Fiducial marker guided prostate radiotherapy can be used 7) Hydrogel spacers are implanted 8) Able to insert indwelling bladder catheter 9) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Treated with brachytherapy 2) Received anti-androgen therapy for more than 1 year 3) After radical prostatectomy 4) MRI cannot be performed 5) Inflammatory bowel disease 6) Bilateral total hip arthroplasty 7) Synchronous or metachronous malignancies 8) Prostate volume larger than 80 cm3 on planning CT 9) Patients who attending physicians consider to be inappropriate due to other reasons mentioned above

Design outcomes

Primary

Measure	Time frame
Five-year biochemical relapse-free survival	—

Countries

Japan

Contacts

Public ContactKoyo Kikuchi

Iwate medical university Department of radiation oncology

kikuchi@iwate-med.ac.jp019-613-7111

Outcome results